Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This limits the proliferation of rapidly dividing cells such as immune cells and malignant tumor cells, providing both immunosuppressive and antineoplastic effects.

The dose of Metoject is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and response to therapy. Only a qualified health professional should set the dosing regimen.

Metoject is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and death. It is also not recommended while breastfeeding, as methotrexate can be excreted in breast milk and may harm the infant.

To order Metoject, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metoject (methotrexate) is an antimetabolite, whereas many alternatives for rheumatoid arthritis are biologic agents such as TNF‑alpha inhibitors. Methotrexate is generally less expensive and administered orally or by injection, but biologics may offer faster symptom control for patients who do not respond adequately to methotrexate.

Metoject should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from light, moisture and extreme temperatures. Do not freeze. Follow standard aseptic techniques when preparing the injectable solution for administration.

Metoject is supplied as an injectable solution and can be given by intramuscular, intravenous, or subcutaneous injection. The route, site and frequency are determined by the prescribing clinician and should be performed by a qualified health‑care professional following aseptic procedures.

Serious risks include severe bone marrow suppression leading to pancytopenia, hepatotoxicity that can progress to cirrhosis, and pulmonary fibrosis. Patients should be monitored regularly for blood counts, liver function tests and respiratory symptoms, and therapy should be stopped if any of these severe reactions occur.

Metoject should not be used by pregnant women, individuals with severe renal or hepatic impairment, patients with pre‑existing bone marrow disorders, or those receiving live vaccines. It is also contraindicated in patients with known hypersensitivity to methotrexate or any component of the formulation.